From GlobeNewswire: 2025-03-12 16:05:00

BeautyHealth, home to Hydrafacial, reported Q4 2024 financial results, exceeding guidance with $9 million adjusted EBITDA and 34,000 global delivery systems. 2025 focus includes partnerships, innovation, and growth. Full year 2024 net sales were $334.3 million, gross margin 54.5%, and active install base grew to 34,735 units. Financial guidance for 2025 predicts net sales of $270-$300 million and adjusted EBITDA of $10-$25 million.

Challenging macroeconomic conditions impacted BeautyHealth’s Q4 2024 results, with net sales at $83.5 million, a decrease from the previous year. Adjusted EBITDA improved to $9 million. The company placed 1,087 delivery systems compared to 1,551 in the prior year. Full-year 2024 net sales were $334.3 million, with an adjusted EBITDA of $12.3 million.

BeautyHealth’s financials showed a gross margin of 62.7% in Q4 2024, up from 47.2% in Q4 2023. Adjusted gross margin was 67.1% in Q4 2024. Full-year 2024 gross margin was 54.5%. The company had $370.1 million in cash, cash equivalents, and restricted cash as of December 31, 2024, compared to $523.0 million in 2023.

The Beauty Health Company’s financial guidance for 2025 reflects a focus on consumable net sales due to downward pressure on delivery systems sales. Excludes unforeseen circumstances. Regional metrics show net sales breakdown by region. BeautyHealth will host a conference call on March 12, 2025, to discuss financial results. Non-GAAP financial measures are used for evaluation and forecasting. Adjusted gross profit and EBITDA are key metrics used by the company.



Read more at GlobeNewswire:: BeautyHealth Reports Full Year and Fourth Quarter 2024